That's a very interesting point. You'd see a scalloped KM curve, which is potentially particularly tricky with a scallop right near the median. I was wondering how you could get such a good HR with such a small increase in TTP.
But their preliminary HR on OS is still very good. Maybe the crossover won't make such a difference because these patients just don't have much time after confirmed progression.
BTW, I noted a higher PFS (1.7) than TTP (1.6) in the ITT drug group. How is that possible?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.